Financials

  • Market Capitalization 1.5418 B
  • Employee 6 600
  • Founded 1979
  • CEO Douglas C Bryant
  • Website www.quidelortho.com
  • Headquarter California, United States
  • FIGI BBG017TGV7M2
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-1.76
Price to sales ratio
0.73
Dividends per share
Dividend yield %

QuidelOrtho Corporation

QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide. On May 8, 2020 the U.S. Food and Drug Administration issued to Quidel the first emergency use authorization for a COVID-19 rapid antigen test, a new category of tests for use in the ongoing pandemic. These diagnostic tests quickly detect fragments of proteins found on or within the virus by testing samples collected from the nasal cavity using swabs.

뉴스